



BIOTECH SUPPORT GROUP
Sample Prep that Matters

CANCER PROTEOMICS APPLICATION REPORT

POSTER REPRINT FIRST PRESENTED AT AACR ANNUAL MEETING 2016
CONFERENCE, HELD APRIL 17-20, 2016 NEW ORLEANS, LA USA

The Commonality of the Cancer Serum Proteome Phenotype as analyzed by LC-MS/MS, and Its Application to Monitor Dysregulated Wellness

Haiyan Zheng¹; Caifeng Zhao¹; Swapan Roy²; Devjit Roy MD; Amenah Soherwardy²; Ravish Amin²; Matthew Kuruc²
¹Rutgers Center for Integrative Proteomics, Piscataway, NJ; ²Biotech Support Group LLC, Monmouth Junction, NJ

Introduction and Objectives

For many diseases, pancreatic cancer for example, long term survival is critically dependent upon early detection. So various strategies for early detectable markers are being investigated. One such strategy is to identify a singular biomarker, derived from genomic analysis, and then determine its derivative protein concentration in blood. This has been challenging as many differentially regulated genes do not generate a differentially regulated protein. An alternative biomarker strategy is to consider panels of proteins as up and/or down regulated biomarkers, which differ in diseased and normal states. Following this strategy, many serum proteomic investigations have analyzed one cancer type or another, but our goal was to consider whether patterns of multiple proteins dysregulated in cancer could be observed regardless of the primary tumor, stage of progression or tumor burden. In this study we adopted a relatively new method, which combines Albumin depletion and on-bead digestion of the depleted serum in a seamless process, called **AlbuVoid™ LC-MS On-Bead**. From this method, we were able to compare isobaric labeled quantification of proteins, using LC-MS/MS from normal and disease state sera – for this case, breast, lung and pancreatic cancer. The methods spectrally quantified over 200 total proteins, and most notably enriched for sub-populations of the protease inhibitor Alpha-1-Antitrypsin, which as a ratio of bead-bound fractions to unbound fractions, is severely dysregulated in the cancer samples. From this data, we solicit that biomarkers from categorical panels can distinguish a cancer serum phenotype at very early stages, possibly even before presentation of any clinical evidence. Such ability to monitor dysregulation from wellness can now be refined by future more detailed cancer sera investigations.

For such a strategy to be viable, most proteins from normal/healthy sera should be within a small and consistent variance taking into account both technical and biological variance for the proteins measured. This has been established previously with the methods reported here¹. With confidence that variance of normal is limited, a panel of proteins can be selected that are observed to be dysregulated (either up, down, or cyclical up/down) within the disease state; defining in our case a cancer phenotype. We cite one report supporting such a strategy using multiple protein markers in a risk prediction

model for lung cancer in lieu of stand-alone tests². Yet in almost all previous studies, only one primary tumor site (lung or pancreas for example) was considered in the study. Notably, we found only one report which considers the common proteomic patterns of three cancer primary tumor sites - breast, colon and lung, revealing distinctive expression of acute-phase proteins³. Similarly, others report on a hyper-coagulation state with many cancers⁴. This suggests the feasibility of our goal, revealing a measurable cancer phenotype in serum, without regard to primary tumor of origin, clinical stage of progression, or tumor burden.

In our prior report, 3 cancer types – pancreatic (Pancr), breast (Brst) and lung cancer, with sera taken from clinically characterized stages I – IV, were compared against a pooled sera from matched 5 normal/healthy individuals of similar age and sex, in this case females, ages 40-60. In like manner, we also considered the variance within these same normal/healthy individuals to account for any combined technical and biological variance with our methods. A discussion of how these observations compare to previous observations by others and areas for future research has been reported previously¹.

One particular observation stood out. The protein identified as SERPINA1 and more commonly known as Alpha-1-Antitrypsin (AAT) was down-regulated in all cancer samples tested, and in most cases, such down-regulation was severe – twofold or more relative to the normal reference. This contrasts to other reports that cite this protein as being up-regulated in cancer and inflammation, except when gene mutation drives functional inactivation. As we suspected what we were observing was a distinctive sub-population, a second series of tests herein reported, support our important conclusion that different sub-populations of Alpha-1-Antitrypsin are dysregulated in the cancer sera.

Methods

Test 1 Methods

The basic workflow considered:

- Albumin Removal and low abundance bead bound enrichment of remaining sub-proteome (without Albumin)
- On-Bead Digestion, 4 hours to minimize proteolytic background
- Single 3 hour LC-MS, no peptide level fractionation
- TMT labels, ratio cancer/normal thresholds >1.5 up-regulated, <0.7 down-regulated
- >200 Proteins observed

A detailed analysis of the methods and the biomarker proteins has been previously documented as a poster report first presented at the 12th Annual US HUPO Conference, March 13-16, 2016. A reprint is available from the company website¹.

Test 1 Results and Discussion

We note two reports that a collection of blood based biomarkers measuring inflammatory and acute phase response proteins, measured within a panel rather than singular tests, can model early detection of cancer 2 to 3 years prior to clinical evidence^{2,5}. Our initial study supports others that describe common dysregulated functions within the cancer phenotype, regardless of the primary tumor or tumor burden. We similarly found *inflammatory*, *coagulation*, and *tissue remodeling* biomarkers which

are common to the 3 primary tumors tested and possibly common to the majority of primary tumors¹. With the exception of **glycolysis** which is likely derived from tumor burden, such functional dysregulation within blood may serve a supportive pre-malignancy microenvironment necessary for cancer progression. We also observed proteins not previously reported with cancer associations, along with several with little or no previous annotation to serum/plasma at all; 2 of which were theoretical only based on gene sequence, and not previously reported at the protein level in the public domain. We categorize these proteins as **unknown** function.

AlbuVoid™ Methods Reveal Altered Cancer Associate Protein Levels Categorized into 5 Separate Biomarker Panels:

- **Inflammation**
- **Coagulation**
- **Tissue Remodeling**
- **Glycolysis**
- **Unknown**

A representative list of some of these categorical biomarkers are shown in Table 1.

Table 1. Representative List of Categorical Cancer Serum Biomarkers

Protein ID	Protein Description	Category	# Individuals Threshold /All	Cancer Types	Comments
CRP	C-reactive protein	Inflammation	7/11 Up-regulated	Pancr, Breast, Lung All Stages	Acute phase response protein, may scavenge nuclear material released from damaged circulating cells. Others report up-regulated in cancer (6) (7)
PIGR	Polymeric immunoglobulin receptor	Inflammation	3/5 Up-regulated	Pancr, All Stages	Mediates transcellular transport of polymeric immunoglobulins. Others report up-regulated in cancer (8) (9)
SEMA3D	Sema domain immunoglobulin secreted 3D	Inflammation	3/3 Down-regulated	Lung All Stages	Neural development, may have role in immune function. No known reports of cancer association.
IGLV3-27	Ig-like	Inflammation	9/10 5/5 Stg 1 Down-regulated	Pancr, Breast, Lung All Stages	Immunoglobulin. No known previous reports of cancer association
PF4	Platelet Factor 4	Inflammation Coagulation	13/13 9/13 severe Up-regulated	Pancr, Breast, Lung All Stages	Promotes blood coagulation, may play role in wound repair and inflammation. Others report up-regulated in cancer (10) (11) (12)
PPBP	Beta thromboglobulin aka CTAPIII/NAP-2	Coagulation	13/13 9/13 severe Up-regulated	Pancr, Breast, Lung All Stages	Platelet activation. Elevated levels predated lung cancer diagnosis by 29 months, with cyclical levels upon surgical resection and recurrent disease (2)
CLU	Clusterin	Tissue Remodeling	12/13 Up-regulated	Pancr, Breast, Lung All Stages	Multiple isoforms, associated with clearance of cellular debris and tissue remodeling. Up & down regulation have been described for many cancers, may be isoform specific (3) (13)

Table 1 (Continued). Representative List of Categorical Cancer Serum Biomarkers


Protein ID	Protein Description	Category	# Individuals Threshold /All	Cancer Types	Comments
CPN1	Carboxypeptidase N, serum	Tissue Remodeling	10/13 Up-regulated	Pancr, Breast, Lung All Stages	metallo-protease No known previous reports of cancer association
SERPIN G1	serpin peptidase inhibitor, clade G (C1 inhibitor), member 1	Tissue Remodeling Inflammation	12/13 Up-regulated	Pancr, Breast, Lung All Stages	protease inhibitor, levels rise ~2-fold during inflammation Others report Up-regulation in lung cancer (7)
SERPIN A1	Alpha-1-antitrypsin (AAT)	Tissue Remodeling Inflammation	13/13 9/10 severe Pancreatic, Breast Down-regulated	Pancr, Breast, Lung, All Stages	Concentration can rise manyfold upon acute inflammation. Reports of up-regulation in cancer (14), and mutation driven down-regulation in emphysema and cancer (15). We observe strong down-regulation, severe in Breast and Pancreatic; suspect measuring sub-populations and not total populations
PFKM	Phosphofructokinase 1	Glycolysis	5/5 Up-regulated	Pancr, Breast, Stage 1	Key regulatory and rate limiting step of glycolysis (Warburg effect), unexpected cytosolic protein in serum/plasma. Glycolysis pathway observed in cancer sera by 2DE/LC-MS & functional proteomics (16) (17)
C18orf63	No annotation, simply called Uncharacterized	Unknown Function	Up-regulated	Pancr, Breast, Lung All Stages	Not consistently observed with low spectral counts, but outliers are highly up-regulated
CFAP61	Cilia- and flagella-associated protein 61	Unknown Function	7/8 Down-regulated	Pancr, Breast, All Stages	not observed in Peptide Atlas in Human Plasma
CTD-2007N20.1	No annotation	Unknown Function	6/8 Down-regulated	Pancr, Breast, All Stages	Not observed at the protein level in public data. Ensembl gene annotation: Immunoglobulin (Ig) and T-cell receptor (TcR)

Considerations for Test 2 – Testing for Sub-populations of Alpha-1-Antitrypsin

The interesting results that many cancer associated proteins fall into categories led us to consider the impact of those categories on our goal – to establish a cancer serum phenotype protein panel that could be monitored over time; threshold values to which would signal a dysregulation from wellness and trigger a deeper clinical evaluation. One particular protein – SERPINA1, also known as Alpha-1-Antitrypsin (AAT) in the category of **tissue remodeling** stood out. For several reason AAT was particularly interesting to us; its consistency in all 13 cancer individuals tested, the severity of the dysregulation and most importantly, the contradiction of our observations with those of others. As we were in essence performing a protein level separation by our methods, we suspected that what we might be observing was not the total AAT population, but a fractionated sub-population. So additional tests considered where these different sub-populations might fractionate and how they might be reported.

The SERPIN superfamily of proteins


Tissue remodeling is an essential feature of cancer, and proteases play a key role. Consequently, the balance and regulation of proteolytic activity is essential to biomarker discoveries and possibly to therapeutic intervention. Many of these regulating proteins fall under the SERPIN superfamily of suicidal protease inhibitors. One such inhibitor SERPINA1, known more commonly as Alpha-1-Antitrypsin (AAT), has several isoforms observed in plasma using 2-DE¹⁸. Others report conformational properties of AAT having multiple effects on tumor cell viability and diverse roles in tumorigenesis, suggesting such isoforms may display a specific basis for diagnosis of cancer^{14,19,20}. Yet, most often in proteomics, all sub-populations of AAT are rolled into and counted as one homogeneous population, or as in the case of immuno-depletion, simply ignored as background noise. As a result, the regulation, balance and dynamism within these systems and its impact on disease progression cannot be properly investigated. As an example, AAT substrates can activate proMMP-2, a metalloproteinase involved in tumor invasion and angiogenesis²¹. Key sub-populations of the SERPIN superfamily of protease inhibitors are represented here²².



Current proteomic methods inadequately count the many differential sub-populations (also known as proteoforms) of key protease inhibitors in serum. From the data observed and reported in Table 1, on our first series of tests we suspected that our methods had enriched for a sub-population of AAT. To further validate this hypothesis, we report on a second series of tests; to determine if a second sub-population distinguishable by peptide reporting features could be observed in the unbound (or flow-through), distinct from the bead-bound to which we initially observed. For this second test, we only considered a pooled pancreatic cancer serum vs. a pooled normal control serum.


Methods for Test 2

TMT labels were applied to the tryptic peptides generated from paired samples: pooled pancreatic cancer sera (n=5), and normal/healthy, age & sex matched pooled individuals (n=5). The separation protocols were the same as in Test 1. Digest methods for the bead were the same as in Test 1. As we also analyzed the Flow-through from the beads (the unbound fraction) and Untreated, 2ul serum equivalent of AlbuVoid™ Flow-through and Load (Untreated) were run on SDS-PAGE as gel plugs and in-gel digested with trypsin using standard protocols.



Variant Sub-populations of Alpha-1-Antitrypsin (AAT) severely distinguished In Cancer Serum Phenotype


Bead-bound sub-population
severely down-regulated in
cancer.
LC-MS reports intact
RCL peptide region



AlbuVoid™ Protein Level Separation



Flow-through sub-
population up-regulated
in cancer.
LC-MS reports cleaved
RCL peptides in Flow-
through



Remaining for future investigation are the peptide level features that report the covalently modified protease substrate complex

We solicit that for the first time, our methods have unraveled sub-populations distinguishing an **intact RCL region sub-population** from a **cleaved RCL region sub-population**.

AAT TMT Ratio: Pooled Pancreatic Cancer / Pooled Normal									
Sp Ct = Peptide Spectral Counts									
AAT Peptide Region	start	Amino acid sequence	end	Bead Bound		Flow-Through (Unbound)		Serum Untreated	
				TMT Ratio	Sp Ct	TMT Ratio	Sp Ct	TMT Ratio	Sp Ct
Adjacent RCL Tryptic	360	AVLTIDEK	367	0.35	9	1.78	21	1.53	14
RCL Cleaved	368	GTEAAGAMFLEAIPM	382			1.05	7	1.16	23
RCL Intact	368	GTEAAGAMFLEAIPMSIPPEVK	389	0.77	5	1.75	1	1.34	50
RCL Cleaved	383	SIPPEVK	389			1.45	27	1.44	18
Total all peptide features				0.54	132	1.57	372	1.44	460

The amino acid region of the RCL is 368-392, so the adjacent RCL tryptic peptide at Lys367, highlighted in gray serves as a good comparison between the 3 observable serum populations:

- **Bead-Bound** – The sub-population of proteins that bind and are observed by the AlbuVoid™ on-bead methods
- **Flow-Through (Unbound)** – The sub-population of proteins that flow-through the AlbuVoid™ beads, unbound
- **Untreated** – The total population of proteins that are observable in serum without any sample enrichment, that is without the use of AlbuVoid™

Highlighted in orange is the RCL intact peptide. Highlighted in green are the two RCL peptides that are cleaved at Met382, during suicidal substrate interaction²³; note that these peptides were not observed in the Bead-Bound fraction. These data suggest that the overall AAT population is dominated by the sub-population up-regulated and collected in the Flow-through fraction of AlbuVoid™, and this same sub-population dominates the analysis when untreated sera is investigated. Such is the case in acute AAT up-regulation commonly observed with malignancies and inflammation^{14,20,24}. However, using our methods we distinguish a sub-population separated by the bead and reporting with the bound fraction, as being severely down-regulated with cancer! While this observation may have potential biological significance, no conclusion about the particular cancer-specific proteoform uncovered can be made at this time. Nevertheless, from a biomarker perspective, this serves an additional multiplier benefit; measured as a ratio, these two sub-populations may be the most distinguishable pattern of early dysregulation observable in the cancer serum phenotype to date. For this analysis, the ratio of the Adjacent RCL Tryptic peptide region would be $1.78/0.35=5$. Additional tests report a similar pattern for all three primary tumors, lung, breast as well as pancreas, suggesting that this dysregulated AAT ratio phenotype is common to many if not most primary tumors. As isobaric label ratios in discovery methods can sometimes compress the reporting difference, this ratio may become much greater once more targeted quantitative methods are developed, a goal of future tests.

Conclusions

- Whole new fields of cancer biomarker discoveries rests in the data-rich features of the diverse variety of conformational and proteoform variants associated with classical high abundance proteins like the SERPIN superfamily (i.e., Alpha-1-Antitrypsin). Being nothing short of an interference biomolecule, AAT for example, is quite often immuno-depleted prior to LC-MS. More generally, mid to high abundance proteins are quantified as one homogeneous population, negating the disease specificity that can be obtained through the discreet quantification of the multiple sub-populations available to measure. Our methods begin to unravel and sort these variant sub-populations (also known as proteoforms) so that peptide reporting functional features can distinguish these with more detail, leading to characteristic disease profiles.
- Future investigations will consider the refinement of the reporting features of AAT proteoforms at peptide and functional levels, to distinguish sub-population signatures of Alpha-1-Antitrypsin in cancer. Such new reporting features may serve as a model for the SERPIN superfamily of suicidal protease inhibitors, many of which are involved in cancer and other disease pathologies.

- Finally, we solicit that there is a measurable serum cancer phenotype that can be modeled with categorical proteins taken from inflammation, blood coagulation, tissue remodeling, glycolysis, as well new markers of unknown function. Within this framework, we suggest it feasible to baseline monitor normal/healthy individuals and determine a dysregulation pattern associated with cancer generally but not necessarily for a particular primary tumor. Under the guidance of a physician, such dysregulated patterns may serve as a 'liquid biopsy', forming an early indicator for cancer before clinical evidence. These same patterns may be prognostic and even offer therapy guidance. More refined algorithms for each of these purposes: early detection, prognosis and therapeutic options, can be made with a more detailed investigation in the future. We welcome inquiries in this regard.

For more information, contact:

Matt Kuruc

mkuruc@biotechsupportgroup.com

Tel: 732-274-2866

www.biotechsupportgroup.com

Acknowledgement: We thank Dr. Andrew Thompson at Proteome Sciences plc (Surrey UK) for donating the TMT-6 labels.

References

1. Haiyan Zheng; Caifeng Zhao; Swapan Roy; Devjit Roy MD; Amenah Soherwardy; Ravish Amin; Matthew Kuruc. The Comparison of the Serum Proteome in Individuals with Cancers versus those without Cancer, and its application to Wellness. Poster presented at 12th Annual US HUPO 2016 Conference, held March 13 – 16, 2016 Boston, MA, USA.
<http://www.biotechsupportgroup.com/v/vspfiles/templates/257/pdf/US%20HUPO%20Cancer%20Phenotype%20Poster.pdf>
2. Yee et al. Connective Tissue-Activating Peptide III: A Novel Blood Biomarker for Early Lung Cancer Detection. *J Clin Onc.* Vol 27:17, June 2009.
3. Dowling, P, et al. Analysis of acute-phase proteins, AHSG, C3 CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. *Int J Cancer.* 131, 911-932 (2012).
4. Harold F. Dvorak, M.D. Tumors: Wounds That Do Not Heal. *N Engl J Med* 1986; 315:1650-1659. DOI: 10.1056/NEJM198612253152606
5. Opstal-van Winden AWJ, et al. Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study. *BMC Cancer* 2011, 11:381.
6. Mehan et al. Validation of a blood protein signature for non-small cell lung cancer. *Clinical Proteomics.* 2014**11**:32. DOI: 10.1186/1559-0275-11-32
7. Zeng X, et al. Lung Cancer Serum Biomarker Discovery Using Label Free LC-MS/MS. *J Thorac. Onco.* 2011 April;6(4): 725-734. doi:10.1097/JTO.0b013e31820c312e.
8. Tonack et al. iTRAQ reveals candidate pancreatic cancer serum biomarkers; influence of obstructive jaundice on their performance. *BJC* (2013) 108, 1846-1853.
9. Ai J, et al. The Role of Polymeric Immunoglobulin Receptor in Inflammation-Induced Tumor Metastasis of Human Hepatocellular Carcinoma. *JNCI* 103:22 Nov 2011.
10. Poruk KE, et al. Serum Platelet Factor 4 is an Independent Predictor of Survival and Venous Thromboembolism in Patients with Pancreatic Adenocarcinoma. *Cancer Epidemiol Biomarkers Prev.* 2010. October; 19(10): 2605-2610.
11. Solasso J, et al. Serum protein signature may improve detection of ductal carcinoma in situ of the breast. *Oncogene* (2010) 29, 550-560.
12. Fiedler GM, Leichtle AB, Kase J, et al. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating peptide associated with pancreatic cancer. *Clin Cancer Res* 2009; 15:3812-9
13. Ana M. Rodriguez-Pineiro, Maria Paez de la Cadena, Angel Lopez-Saco, and Francisco J. Rodriguez-Berroca. Differential Expression of Serum Clusterin Isoforms in Colorectal Cancer. *Mol Cel Proteomics.* Sept 2006, 1647-1657.
14. Wang Y, et al. Screening for serological biomarkers of pancreatic cancer by two-dimensional electrophoresis and liquid chromatography-tandem mass spectrometry. *Oncology Reports* 26: 287-292, 2011.
15. Saunders DN, et al. A novel SERPINA1 mutation causing serum alpha(1)-antitrypsin deficiency. *PLoS One* 2012, 7:e51762
16. Mikuyira K, et al. Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. *INTERNATIONAL JOURNAL OF ONCOLOGY* 30: 849-855, 2007 849.

17. Xing Wang, Michael Davies, Swapan Roy, and Matthew Kuruc. Bead Based Proteome Enrichment Enhances Features of the Protein Elution Plate (PEP) for Functional Proteomic Profiling. *Proteomes* **2015**, 3(4), 454-466.
<http://www.mdpi.com/2227-7382/3/4/454>
18. Mateos-Caceres PJ, et al. Proteomic Analysis of plasma from patients during an acute coronary syndrome. *J Am Coll Cardiol* 44: 1578-1583, 2004.
19. Zelvyte I, Sjogren HO, and Janciauskiene S. Effects of native and cleaved form of alpha1-antitrypsin on ME 1477 tumor cell functional activity. *Cancer Detect Prev* 26: 256-265, 2002.
20. Janciauskiene A. Conformational properties of serine proteinase inhibitors (serpins) confer multiple pathophysiological roles. *Biochimica et Biophysica Acta* 1535 (2001) 221-235.
21. Shamamian P, et al. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: A role for inflammatory cells in tumor invasion and angiogenesis. *J Cell Physiol* 189 (2), 197-206 (2001).
22. Law RHP, et al. An overview of the serpin superfamily. *Genome Biology* 2006, 7:216. doi:10.1186/gb-2006-7-5-216.
23. Frochoux V, et al. Alpha-1-Antitrypsin: A Novel Human High Temperature Requirement Protease A1 (HTRA1) Substrate in Human Placental Tissue. *PLoS ONE* 9(10): e109483. doi:10.1371/journal.pone.0109483.
24. Travis J. Structure, function, and control of neutrophil proteinases. *A, J. Med.* 84 (1988) 37-42.